CHANGES IN DRUG AND ALCOHOL USE AND INJECTION RISK BEHAVIOURS AMONG PEOPLE WHO INJECT DRUGS DURING AND FOLLOWING HCV DIRECT-ACTING ANTIVIRAL TREATMENT: THE SIMPLIFY AND D3FEAT STUDIES

Authors:
Artenie AA1,2, Cunningham EB3, Conway B4, Dalgard O5, Powis J6, Bruggmann P7, Hellard ME8,9, Cooper C10, Read P3,11 Feld JJ12, Hajarizadeh B3, Amin J3,13, Applegate TL3, Lacombe K14, Stedman C15, Dunlop A16, Litwin AH17,18, Marks P3, Matthews GV3,19, Quiene S3, Erratt A3, Dore GJ3,9, Bruneau J1,2*, Grebely J3*
*contributed equally

1Université de Montréal, Montréal, Canada; 2Research Centre, Centre Hospitalier de l'Université de Montréal; 3The Kirby Institute, UNSW Sydney, Sydney, Australia; 4Vancouver Infectious Diseases Center, Vancouver, Canada; 5Akershus University Hospital, Oslo, Norway; 6South Riverdale Community Health Centre, Toronto, Canada; 7Arud Centres for Addiction Medicine, Zurich, Switzerland; 8The Burnet Institute, Melbourne, Australia; 9The Alfred Hospital, Melbourne, Australia; 10Ottawa Hospital Research Institute, Ottawa, Canada; 11Kirketon Road Centre, Sydney, Australia; 12Toronto General Hospital, Toronto, Canada; 13Macquarie University, Sydney, Australia; 14Hôpital Saint-Antoine, Paris, France; 15Christchurch Hospital and University of Otago, Christchurch, New Zealand; 16Newcastle Pharmacotherapy Service, Newcastle, Australia; 17Montefiore Medical Centre, New York, United States; 18Albert Einstein College of Medicine, New York, United States; 19St Vincent’s Hospital, Sydney Australia;

Background:
The simplification of HCV treatment with direct-acting antiviral (DAA) therapies has raised concerns regarding possible increases in drug use and risk behaviours among people who inject drugs (PWID) following treatment. Yet, few studies have investigated this question. Our aim was to examine changes in drug and alcohol use and injecting risk behaviours during and following DAA therapy among PWID.

Methods:
SIMPLIFY and D3FEAT are phase IV clinical trials evaluating the efficacy of DAA therapy among PWID with recent injecting drug use (last six months) or those receiving opiate agonist therapy (OAT), through a network of 25 international sites (SIMPLIFY: sofosbuvir/velpatasvir for 12 weeks in PWID with recent injecting; D3FEAT: paritaprevir/ritonavir/dasabuvir/ombitasvir±ribavirin for 12 weeks in PWID with recent injecting or receiving OAT). Participants completed a behavioural questionnaire at baseline and follow-up at weeks 4, 8 and 12, 24 (SVR12) and 36 (SVR24). The impact of time in treatment and follow-up on longitudinally measured recent behavioral outcomes was evaluated using generalized estimating equations.

Results:
At baseline, of 190 participants (SIMPLIFY, n=103; D3FEAT, n=87) (mean age: 47; 75% male), 61% reported past-month injecting, and of these, 9% reported needle/syringe sharing. Current OAT was reported by 64% and hazardous alcohol use by 33%. During HCV treatment and follow-up, there was a decrease in most drugs injected: heroin (OR: 0.90 per incremental study visit, 95% CI: 0.85-0.96), other opioids (OR: 0.92, 95%CI: 0.85-1.00) and amphetamine (0.93; 95%CI: 0.87-1.00). No changes were observed for cocaine injection (OR: 1.03, 95%CI: 0.94-1.13) nor hazardous alcohol use (OR: 1.02; 95%CI: 0.96-1.08). Among those injecting, needles/syringe sharing decreased (OR: 0.81, 95%CI: 0.65-1.01).
**Conclusion:** Generally, drug use and injection risk behaviours decreased during and following HCV treatment among PWID. Yet, hazardous alcohol use remained unchanged, suggesting efforts are needed to better integrate alcohol use interventions within HCV care.

**Disclosure of Interest Statement:** See example below:
A. Artenie: None Declared, E. Cunningham: None Declared, B. Conway Grant/Research support from: Gilead Sciences, Merck, and AbbVie, O. Dalgard Grant/Research support from: Gilead Sciences, Merck, and AbbVie, J. Powis: None Declared, P. Bruggmann Grant/Research support from: AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck Sharp & Dohme, M. Hellard Grant/Research support from: Gilead Sciences, Bristol-Myers Squibb, and AbbVie, C. Cooper Grant/Research support from: Gilead Sciences, P. Read: None Declared, J. Feld Grant/Research support from: AbbVie, Merck, Gilead Sciences, Janssen and Abbott, B. Hajarizadeh: None Declared, J. Amin: None Declared, T. Applegate: None Declared, A. Litwin Grant/Research support from: Gilead Sciences and Merck, P. Marks: None Declared, G. Matthews Grant/Research support from: Gilead Sciences and AbbVie, S. Quiene: None Declared, G. Dore Grant/Research support from: AbbVie, Merck, Bristol-Myers Squibb, Roche and Janssen, J. Bruneau Consultant for: Gilead Sciences and Merck, J. Grebely Grant/Research support from: AbbVie, Cepheid, Gilead Sciences, and Merck